Replies to post #230609 on Biotech Values

[miljenko]

Humabs BioMed (VIR) work (early, 2004) on SARS-CoV-1, where they isolate neutralizing abs binding into conformational changed (activated) Spike-RB S2 domain:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095806/
and in 2015 on MERS-CoV: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4547275/
Latest , more sophisticated article in Cell, 2019 (MERS and SARS combination work), https://www.ncbi.nlm.nih.gov/pubmed/30712865

Interesting, they do not have US/EU patent or patent application on SARS/MERS Abs.